Striatal dopamine-NMDA receptor interactions in the modulation of glutamate release in the substantia nigra pars reticulata in vivo: Opposite role for D1 and D2 receptors

Journal of Neurochemistry

Volumn 83, Issue 3, 2002, Pages 635-644

  Marti, Matteo ^a   Mela, Flora ^a   Bianchi, Clementina ^a   Beani, Lorenzo ^a   Morari, Michele ^a  

^a UNIVERSITY OF FERRARA   (Italy)

Author keywords

6 hydroxydopamine; Dopamine; Glutamate; Microdialysis; NMDA; Substantia nigra

Indexed keywords

8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; DIZOCILPINE; DOPAMINE; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; GLUTAMIC ACID; N METHYL DEXTRO ASPARTIC ACID; OXIDOPAMINE; RACLOPRIDE; TETRODOTOXIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINERGIC TRANSMISSION; MALE; MICRODIALYSIS; NONHUMAN; PARKINSON DISEASE; PARKINSONISM; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN INTERACTION; RAT; SIGNAL TRANSDUCTION; SUBSTANTIA NIGRA;

ANIMALS; CORPUS STRIATUM; DISEASE MODELS, ANIMAL; DOPAMINE; DOPAMINE ANTAGONISTS; GLUTAMIC ACID; MALE; MICRODIALYSIS; N-METHYLASPARTATE; OXIDOPAMINE; PARKINSONIAN DISORDERS; PERFUSION; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, DOPAMINE D1; RECEPTORS, DOPAMINE D2; RECEPTORS, N-METHYL-D-ASPARTATE; SUBSTANTIA NIGRA; WAKEFULNESS;

ANIMALIA;

EID: 0036828352     PISSN: 00223042     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1471-4159.2002.01169.x     Document Type: Article

References (74)

1. Albin R. L., Young A. B. and Penney J. B. (1989) The functional anatomy of basal ganglia disorders. Trends Neurosci. 12, 366-375.
2. Bergman H., Wichmann T. and DeLong M. R. (1990) Reversal of experimental parkinsonism by lesions of the subthalamic nucleus. Science 249, 1436-1438.
3. 2 receptors via the indirect striatal output pathway? Brain Res. 753, 163-175.
4. Blank T., Nijholt I., Teichert U., Kugler H., Behrsing H., Fienberg A., Greengard P. and Spiess J. (1997) The phosphoprotein DARPP-32 mediates cAMP-dependent potentiation of striatal N-methyl-Daspartate responses. Proc. Natl. Acad. Sci. USA 94, 14859-14864.
5. Cadet J. L. and Zhu S. M. (1992) The intrastriatal 6-hydroxydopamine model of hemiparkinson: Quantitative receptor autoradiographic evidence of correlation between circling behavior and presynaptic as well as postsynaptic nigrostriatal markers in the rats. Brain Res. 595, 316-326.
6. Calabresi P., Pisani A., Centonze D. and Bernardi G. (1996) The corticostriatal projection: From synaptic plasticity to dysfunctions of the basal ganglia. Trends Neurosci. 19, 19-24.
7. Calabresi P., Saiardi A., Pisani A., Baik J.-H., Centonze D., Mercuri N., Bernardi G. and Borrelli E. (1997) Abnormal synaptic plasticity in the striatum of mice lacking dopamine D2 receptors. J. Neurosci. 17, 4536-4544.
8. Calè G., Sbrenna S., Bianchi C. and Beani L. (1997) Immediate and delayed effects of in vitro ischemia on glutamate efflux from guinea-pig cerebral cortex slices. Brain Res. 751, 300-306.
9. Cepeda C. and Levine M. S. (1998) Dopamine and N-methyl-D-aspartate receptor interactions in the neostriatum. Dev. Neurosci. 20, 1-18.
10. Cepeda C., Buchwald N. A. and Levine M. S. (1993) Neuromodulatory actions of dopamine in the neostriatum are dependent upon the excitatory amino acid receptor subtypes activated. Proc. Natl. Acad. Sci. USA 90, 9576-9580.
11. Cepeda C., Colwell C. S., Itri J. N., Chandler S. H. and Levine M. S. (1998) Dopaminergic modulation of NMDA-induced whole cell current in neostriatal neurons in slices: Contribution of calcium conductances. J Neurophysiol. 79, 82-94.
12. Cepeda C., Hurst R. S., Altemus K. L., Flores-Hernandez J., Calvert C. R., Jokel E. S., Grandy D. K., Low M. J., Rubinstein M., Ariano M. A. and Levine M. S. (2001) Facilitated glutamatergic transmission in the striatum of D2 dopamine receptor-deficient mice. J. Neurophysiol. 85, 659-670.
13. Charpier S. and Deniau J. M. (1997) In vivo activity-dependent plasticity at cortico-striatal connections: Evidence for physiological longterm potentiation. Proc. Natl. Acad. Sci. USA 94, 7036-7040.
14. Chase T. N. and Oh J. D. (2000) Striatal dopamine- and glutamate-mediated dysregulation in experimental parkinsonism. Trends Neurosci. 23, S86-S91.
15. Clark D. and White F. (1987) D1 dopamine receptor - The search for a function: A critical evaluation of the D1/D2 dopamine receptor classification and its functional implications. Synapse 1, 347-388.
16. Delfs J. M., Ciaramitaro V. M., Parry T. J. and Chesselet M.-F. (1995) Subthalamic nucleus lesions: Widespread effects on changes in gene expression induced by nigrostriatal dopamine depletion in rats. J. Neurosci. 15, 6562-6575.
17. Di Chiara G., Morelli M. and Consolo S. (1994) Modulatory functions of neurotransmitters in the striatum: ACh/dopamine/NMDA interactions. Trends Neurosci. 17, 228-233.
18. 2A receptors and dopamine D2 receptors in the ventral striopallidal system. Implications for the treatment of schizophrenia. Neuroscience 63, 765-773.
19. Fraix V., Pollack P., Van Blercom N., Xie J., Krack P., Koudsie A. and Benabid A. L. (2000) Effect of subthalamic nucleus stimulation on levodopa-induced dyskinesia in Parkinson's disease. Neurology 55, 1921-1923.
20. Ganguly A. and Keefe K. A. (2001) Unilateral dopamine depletion increases expression of the 2A subunit of the N-methyl-D-aspartate receptor in enkephalin-positive and enkephalin-negative neurons. Neuroscience 103, 405-412.
21. Gerfen C. R. (1990) D1 and D2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons. Science 250, 1429-1432.
22. Grace A. A. (1991) Phasic versus tonic dopamine release and the modulation of dopamine system responsivity: A hypothesis for the etiology of schizophrenia. Neuroscience 41, 1-24.
23. Halpain S., Girault J.-A. and Greengard P. (1990) Activation of NMDA receptors induces dephosphorylation of DARPP-32 in rat striatal slices. Nature 343, 369-372.
24. Harsing L. G. Jr and Zigmond M. J. (1997) Influence of dopamine on GABA release in striatum: Evidence for D1-D2 interactions and non-synaptic influences. Neuroscience 77, 419-429.
25. 2+ conductance. J. Neurosci. 17, 3334-3342.
26. 2+ currents and excitability via novel PLC β1-IP3-calcineurin-signaling cascade. J. Neurosci. 20, 8987-8995.
27. Hirsch E. C., Perier C., Orieux G., Francois C., Feger J., Yelnik J., Vial M., Levy R., Tolosa E. S., marin C., Herrero M. T., Obeso J. A. and Agid Y. (2000) Metabolic effects of nigrostriatal denervation in basal ganglia. Trends Neurosci. 23, S78-S91.
28. Hollander M. and Wolfe D. A. (1973) Nonparametric Statistical Methods. John Wiley and Sons, New York.
29. Hu X.-T. and White F. J. (1996) Glutamate receptor regulation of rat nucleus accumbens neurons in vivo. Synapse 23, 208-218.
30. Hyttel J. (1983) SCH 23390-the first selective dopamine D-1 antagonist. Eur. J. Pharmacol. 91, 153-154.
31. Jonkers N., Sarre S., Ebinger G. and Michotte Y. (2002) MK801 suppresses the L-DOPA-induced increase of glutamate in striatum of hemi-Parkinson rats. Brain Res. 926, 149-155.
32. Kiyatkin E. A. and Rebec G. V. (1999) Striatal neuronal activity and responsiveness to dopamine and glutamate after selective blockade of D1 and D2 dopamine receptors in freely moving rats. J Neurosci. 19, 3594-3609.
33. Klockgether T. and Turski L. (1993) Toward an understanding of the role of glutamate in experimental parkinsonism: Agonist-sensitive sites in the basal ganglia. Ann. Neurol. 34, 585-593.
34. Kotter R. (1994) Postsynaptic integration of glutamatergic and dopaminergic signals in the striatum. Progr. Neurobiol. 44, 163-196.
35. Landwehrmeyer G. B., Standaert D. G., Testa C. M., Penney J. B. and JrYoung A. B. (1995) NMDA receptor subunit mRNA expression by projection neurons and intemeurons in rat striatum. J. Neurosci. 15, 5297-5307.
36. Leveque J. C., Macias W., Rajadhyaksha A., Carlson R. R., Barczac A., Kang S., Li X.-M., Coyle J. T., Huganir R. L., Hekers S. and Konradi C. (2000) Intracellular modulation of NMDA receptor function by antipsychotic drugs. J. Neurosci. 20, 4011-4020.
37. 1A-deficient mutant mice. J. Neurosci. 16, 5870-5882.
38. Lindroth P. and Mopper K. (1979) High performance liquid chromatographic determination of subpicomole amounts of aminoacids by precolumn fluorescence derivatization with o-phthalaldehyde. Anal. Chem. 51, 1667-1674.
39. Mabuchi T., Kitagawa K., Kuwabara K., Takasawa K., Ohtsuki T., Xia Z., Storm D., Yanagihara T., Hori M. and Matsumoto M. (2001) Phosphorylation of cAMP response element-binding protein in hippocampal neurons as a protective response after exposure to glutamate in vitro and ischemia in vivo. J. Neurosci. 21, 9204-9213.
40. Marti M., Sbrenna S., Fuxe K., Bianchi C., Beani L. and Morari M. (1999) In vitro evidence for increased facilitation of striatal acetylcholine release via pre- and postsynaptic NMDA receptors in hemiparkinsonian rats. J. Neurochem. 72, 875-878.
41. Marti M., Sbrenna S., Fuxe K., Bianchi C., Beani B. and Morari M. (2000) Increased responsitivity of nigral glutamate release to striatal NMDA receptor blockade in a model of Parkinson's disease. A dual probe microdialysis study in hemiparkinsonian rats. Eur. J. Neurosci. 12, 1848-1850.
42. Menegoz M., Lau L., Hervè D., Huganir L. R. and Girault J. (1995) Tyrosine phosphorylation of NMDA receptor in rat striatum: Effects of 6-OH-dopamine lesions. Neuroreport 7, 125-128.
43. Meshul C. K., Emre N., Nakamura C. M., Allen C., Donohue M. K. and Buckman J. F. (1999) Time-dependent changes in striatal glutamate synapses following a 6-hydroxydopamine lesion. Neuroscience 88, 1-16.
44. 2 receptor antagonism differentially modulates stimulation of striatal neurotransmitter levels by N-methyl-D-aspartic acid. Eur. J. Pharmacol. 256, 23-30.
45. Morari M., O'Connor W. T., Darvelid M., Ungerstedt U., Bianchi C. and Fuxe K. (1996) Functional neuroanatomy of the nigrostriatal and the striatonigral pathways as studied with dual probe microdialysis in the awake rat. II. Evidence for a striatal N-methyl-D-aspartate receptor regulation of striatonigral GABAergic transmission and motor function. Neuroscience 72, 89-97.
46. Morari M., Sbrenna S., Marti M., O'Connor W. T., Bianchi C., Fuxe K. and Beani L. (1998) Evidence for a striatal NMDA receptor modulation of nigral glutamate release. A dual probe microdialysis study in the awake freely moving rat. Eur. J. Neurosci. 10, 1716-1722.
47. Morari M., Marti M., Bianchi C. and Beani L. (2001) Striatal dopamine-NMDA interactions in the modulation of glutamate release from the substantia nigra pars reticulata: A dual probe microdialysis study in awake freely moving rats. Soc. Neurosci. Abstract. 26, 1933.
48. Nicola S. M., Surmeier D. J. and Malenka R. C. (2000) Dopaminergic modulation of the neuronal excitability in the striatum and nucleus accumbens. Ann. Rev. Neurosci. 23, 185-215.
49. Obeso J. A., Rodriguez-Oroz M. C., Rodriguez M., Macias R., Alvarez L., Guridi J., Vitek J. and DeLong M. R. (2000) Pathophysiological basis of surgery for Parkinson's disease. Neurology 55, S7-S12.
50. Ossowska K. and Wolfarth S. (1995) Stimulation of glutamate receptors in the intermediate/caudal striatum induces contralateral turning. Eur. J. Pharmacol. 273, 89-97.
51. Parent A. and Hazrati L. (1995) Functional anatomy of the basal ganglia. II. The place of subthalamic nucleus and external pallidum in basal ganglia circuitry. Brain Res. Rev. 20, 128-154.
52. Paxinos G. and Watson C. (1982) The Rat Brain in Stereotaxic Coordinates. Academic Press, Sydney, Australia.
53. 3H]D-aspartate release by D-2 dopamine receptors in rat striatal slices. Synapse 2, 450-456.
54. Robertson G. S., Vincent S. R. and Fibiger H. C. (1992) D1 and D2 dopamine receptors differentially regulate c-fos expression in striatonigral and striatopallidal neurons. Neuroscience 49, 285-296.
55. Robertson G. S., Tham C.-S., Wilson C., Jakubovic A. and Fibiger H. C. (1993) In vivo comparisons of the effects of quinpirole and the putative presynaptic dopaminergic agonist B-HT 920 and SND 919 on striatal dopamine and acetylcholine release. J. Pharmacol. Exp. Ther 264, 1344-1351.
56. Saller C. F. and Salama A. I. (1986) D1 and D2 dopamine receptor blockade: Interactive effects in vitro and in vivo. J. Pharmacol. Exp. Ther 236, 714-720.
57. 3H]3-(2-carboxypiperazin-4-yl)propyl-1-phosphoric acid binding. J. Neurochem. 54, 1926-1933.
58. Schoffelmeer A. N. M., Vanderschuren L. J. M. J., De Vries T. J., Hogenboom F., Wardeh G. and Mulder A. H. (2000) Synergistically interacting dopamine D1 and NMDA receptors mediate nonvesicular transporter-dependent GABA release from rat striatal medium spiny neurons. J. Neurosci. 20, 3496-3503.
59. Schwarting R. K. W. and Huston J. P. (1996) The unilateral 6-hydroxydopamine lesion model in behavioral brain research. Analysis of functional deficits, recovery and treatments. Progr Neurobiol. 50, 275-331.
60. Seeman P. and Van Tol H. H. M. (1994) Dopamine receptor pharmacology. Trends Pharmacol. Sci. 15, 264-270.
61. Sibley D. R. and Monsma F. J. Jr (1992) Molecular biology of dopamine receptors. Trends Pharmacol. Sci. 13, 61-69.
62. Svenningsson P., Lindskog M., Ledent C., Parmentier M., Greengard P., Fredholm B. B. and Fisone G. (2000) Regulation of the phosphorylation of the dopamine- and cAMP-regulated phosphoprotein of 32 kDa in vivo by dopamine D1, dopamine D2, and adenosine A2A receptors. Proc. Natl. Acad. Sci. USA 97, 1856-1860.
63. Taber M. T., Baker G. B. and Fibiger H. C. (1996) Glutamate receptor agonists decrease extracellular dopamine in the rat nucleus accumbens in vivo. Synapse 24, 165-172.
64. Tallaksen-Greene S. J., Wiley R. G. and Albin R. L. (1992) Localization of striatal excitatory amino acid binding site subtypes to striatonigral projection neurons. Brain. Res. 594, 165-170.
65. Tremblay M., Salin P. and Soghomonian J. J. (1995) Effect of 6-OHDA lesions on striatal mRNA levels encoding for glutamate receptor subunits. Neuroreport 6, 2225-2229.
66. Ulas J. and Cotman C. W. (1996) Dopaminergic denervation in the striatum results in elevated expression of NR2A subunit. Neuroreport 7, 1789-1793.
67. Ungerstedt U. and Arbuthnott G. W. (1970) Quantitative recording of rotational behaviour in rats after 6-hydroxydopamine lesions of the nigrostriatal dopamine system. Brain. Res. 24, 485-493.
68. Vila M., Marin C., Ruberg M., Jimenez A., Raisman-Rozari R., Agid Y., Tolosa E. and Hirsch E. C. (1999) Systemic administration of NMDA and AMPA receptor antagonists reverses the neurochemical changes induced by nigrostriatal denervation in the basal ganglia. J. Neurochem. 345, 344-352.
69. Wachtel S. R., Hu X.-T., Galloway M. P. and White F. J. (1989) D1 dopamine receptor stimulation enables the postsynaptic, but not autoreceptor, effect of D2 dopamine agonists in nigrostriatal and mesoaccumbens dopamine system. Synapse 4, 327-346.
70. Walters J. R., Bergstrom D. A., Carlson J. H., Chase T. N. and Braun A. R. (1987) D1 dopamine receptor activation required for post-synaptic expression of D2 agonist effects. Science 236, 719-722.
71. Walters J. R., Ruskin D. N., Allers K. A. and Bergstrom D. A. (2000) Pre- and postsynaptic aspects of dopamine-mediated transmission. Trends Neurosci. 23, S41-S47.
72. 2 receptor activation on activity states and electrophysiological properties of striatal neurons: Studies combining in vivo intracellular recordings and reverse microdialysis. J. Neurosci. 22, 294-304.
73. Wullner U., Testa C. M., Catania M. V., Young A. B. and Penney J. B. (1994) Glutamate receptors in striatum and substantia nigra: Effects of medial forebrain bundle lesions. Brain Res. 645, 98-102.
74. You Z.-B., Herrera-Marschitz M., Petterson E., Nylander I., Goiny M., Shou H.-Z., Kehr J., Godukhin O., Hokfelt T., Terenius L. and Ungerstedt U. (1996) Modulation of neurotransmitter release by cholecystokinin in the neostriatum and substantia nigra of the rat: Regional and receptor specificity. Neuroscience 74, 793-804.